Monthly Archives: July 2012

Patients Wade into the European Pricing Debate

Patient groups are a growing force, not just in the debate around tactical areas of medical specialities, but also on the vital question of pricing and reimbursement rules. But will their voices be heard? Reflector reports. An important third party is struggling to make its voice heard in European pharma discussions. Drug pricing is not […]
Posted in Europe, Global, Guest Blog, healthcare, pricing, Regulatory | Tagged , , , , , | Leave a comment

Biomedical Innovation in Trouble

The time and cost of developing new drugs are rising, venture capitalists make no return on investments in biopharma R&D, and other countries are boosting support in this area while U.S. policy makers propose funding cuts for the National Institutes of Health (NIH). This bleak picture of the “state of biomedical innovation” was painted by […]
Posted in Biotech, FDA, healthcare, leadership, R&D, Technology | Tagged , , , , , | 3 Comments

Innovative Contracting: What's the Verdict?

Industry is finding it harder to secure market access and payer uptake for new products. Innovative contracting may offer a solution. But is it working? Andrea Sobrio reports. How can a pharmaceutical company convince payers that a new treatment is worth budgeting for? Many companies have shifted the weight of their resources to payers and […]
Posted in Global, Guest Blog, Strategy | Tagged , , | Leave a comment

GSK Goes DTC for London Olympics

It’s an unusual sight in the UK — a television commercial for a Big Pharma company. But among the cultural and commercial innovations being attributed to the London Olympic Games is GSK’s first UK consumer-facing corporate brand campaign, showcasing its anti-doping operations. The TV ad debuted on July 16; this week, the company’s campaign went […]
Posted in Advertising, Europe, Global | Tagged , , , , , | 2 Comments

Missed Opportunities in Rare Disease

At CBI’s 7th Annual Rare Disease and Orphan Drug Leadership Congress, speakers and attendees identified areas where pharma can improve the way it approaches rare disease and treatment.
Posted in Corporate Responsibility, Events, leadership, Market Access, patient compliance, patient education, Regulatory | Tagged , , , , | Leave a comment
  • Categories

  • Meta